Russian President Vladimir Putin was told on a visit to Biocad, one of the country’s leading biotech companies, that Russia's quality of research and development and manufacturing meant it could “absolutely compete with foreign counterparts” in the pharmaceutical industry.
Those were the words of Dmitry Morozov, Biocad’s chief executive, as his company’s St Petersburg facilities were visited by Mr Putin and the Kazakh President Nursultan Nazarbayev.
"Russia - a country with a strong scientific heritage - simply has to be among the leading pharmaceutical states"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze